NEW YORK, Sept. 6 – Gene Logic has licensed a pair of its technology platforms and a set of gene targets to a business unit of Belgian drug company UCB Pharma, the companies said on Thursday.

Under the deal, which broadens an existing collaboration inked in 1999, UCB Research, of Cambridge, Mass., will gain access to the BioExpress Module of Gene Logic’s GeneExpress suite plus the Genesis Enterprise System, according to a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.